China Uniquely Suited To Build Pharma 3.0 From The Ground Up As Healthcare Reform Rolls Out
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As the pharmaceutical industry begins to embrace new business models that utilize the newest advances in information technology to achieve better health outcomes, China may be uniquely suited to implement such a system from the ground up, Ernst & Young said during a life sciences roundtable discussion with local reporters in Shanghai March 25